DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The strips deliver results within 5 minutes, applicable to various substances like powders, pills, and residues from bags or cookers.
Delaware is leading the nation with a groundbreaking initiative to combat its drug overdose problem, launching a pilot program this week for the use of combined fentanyl-xylazine testing strips, a product of SIVAD Diagnostic Medical Group.
Key Points:
- The pilot program has introduced the use of combination fentanyl-xylazine testing strips, named HarmGuard FX, developed by SIVAD Diagnostic Medical Group.
- HarmGuard FX strips can identify both fentanyl and xylazine, substances declared an emerging drug threat by the Office of National Drug Control Policy (ONDCP) in April.
Additional Points:
- The HarmGuard FX strips are part of SIVAD’s Harm Stopper Program, providing resources for different stakeholders and a cloud-based portal offering educational resources and information at a national level.
- The program employs geolocation services to provide users with access to local resources in participating states, such as nearby naloxone distribution locations, needle exchanges, counseling, and emergency services.
- Delaware has the third-highest drug overdose death rate per capita in the country, per CDC data.
Conclusion:
- SIVAD’s innovative drug testing strips are being deployed in Delaware with the aim of combating the escalating overdose crisis. The success of this pilot program could pave the way for similar initiatives nationwide.
Psychiatry Latest Posts
- PA’s Misdiagnosis Leads to $3 Million Malpractice Verdict
- FDA Approves Zaynich for cUTI
- Taking High-Dose Vitamin D Daily Over the Long Term Helps Reduce MS Relapses
- Calcium, Vitamin D Supplements Provide ‘Little to No Benefit’ for Aging Bones: Study
- EULAR/PReS Recommendations for the Diagnosis and Management of Still’s Disease, Comprising Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
“Delaware is committed to responding to the opioid crisis with the urgency it demands. We know harm reduction strategies work, and this new test provides another useful tool we can use to protect residents and save lives.”
Lt. Governor Bethany Hall-Long, PhD, RN
Chair
Delaware Behavioral Health Consortium
